Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-368 + tilsotolimod + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
**ABBV-368 + tilsotolimod + nab-paclitaxel** is a combination investigational regimen used in clinical trial settings for advanced solid tumors. - **ABBV-368** is a monoclonal antibody targeting OX40 (tumor necrosis factor receptor superfamily member 4), designed to activate T cells and enhance anti-tumor immunity[1][3]. - **Tilsotolimod (IMO-2125)** is a synthetic oligonucleotide acting as a Toll-like receptor 9 (TLR9) agonist, administered intratumorally to stimulate local innate immune activation and antigen presentation, triggering adaptive anti-tumor immune responses[2]. - **Nab-paclitaxel (Abraxane, paclitaxel albumin-bound)** is a chemotherapeutic agent that stabilizes microtubules, thereby inhibiting mitosis and promoting apoptosis in proliferating tumor cells. The combination aims to co-activate the immune system (ABBV-368 and tilsotolimod) and exert direct cytotoxic effects (nab-paclitaxel), potentially creating a synergistic anti-tumor effect. Its primary indication in available trials is for advanced or metastatic solid tumors, focusing on triple negative breast cancer, head and neck squamous cell carcinoma, and other immunogenic tumors[1][3].
- Other names
- ABBV-368ABBV368ABBV 368tilsotolimodIMO-2125IMO2125IMO 2125nab-paclitaxelAbraxanepaclitaxel albumin-bound
02
Targets
TLR9 (Toll-like receptor 9)TUBB (Tubulin (alpha and beta subunits))CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on ABBV-368 + tilsotolimod + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-368 + tilsotolimod + nab-paclitaxel.